Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative MicroPET and MRI

Stig Palm, Richard M. Enmon, Cornelia Matei, Katherine S. Kolbert, Su Xu, Pat B. Zanzonico, Ronald L. Finn, Jason A. Koutcher, Steven M. Larson, George Sgouros

Research output: Contribution to journalArticle

Abstract

Preclinical biodistribution and pharmacokinetics of investigational radiopharmaceuticals are typically obtained by longitudinal animal studies. These have required the sacrifice of multiple animals at each time point. Advances in small-animal imaging have made it possible to evaluate the biodistribution of radiopharmaceuticals across time in individual animals, in vivo. MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of 90Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma. Methods: Female nude mice were inoculated intraperitoneally with 5.106 ovarian carcinoma cells (SKOV3). Fourteen days after inoculation, 12-18 MBq 86Y-labeled trastuzumab mAb was injected intraperitoneally. Tumor-free mice, injected with 86Y-trastuzumab, and tumor-bearing mice injected with labeled, irrelevant mAb or 86Y-trastuzumab + 100-fold excess unlabeled trastuzumab were used as controls. Eight microPET studies per animal were collected over 72 h. Standard and background images were collected for calibration. MicroPET images were registered with MR images acquired on a 1.5-T whole-body MR scanner. For selected time points, 4.7-T small-animal MR images were also obtained. Images were analyzed and registered using software developed in-house. At completion of imaging, suspected tumor lesions were dissected for histopathologic confirmation. Blood, excised normal organs, and tumor nodules were measured by γ-counting. Tissue uptake was expressed relative to the blood concentration (percentage of injected activity per gram of tissue [%IA/g]/%IA/g blood). 86Y-Trastuzumab pharmacokinetics were used to perform 90Y-trastuzumab dosimetry. Results: Intraperitoneal injection of mAb led to rapid blood-pool uptake (5-9 h) followed by tumor localization (26-32 h), as confirmed by registered MR images. Tumor uptake was greatest for 86Y-trastuzumab (7 ± 1); excess unlabeled trastuzumab yielded a 70% reduction. Tumor uptake for the irrelevant mAb was 0.4 ± 0.1. The concentration in normal organs relative to blood ranged from 0 to 1.4 across all studies, with maximum uptake in spleen. The absorbed dose to the kidneys was 0.31 Gy/MBq 90Y-trastuzumab. The liver received 0.48 Gy/MBq, and the spleen received 0.56 Gy/MBq. Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm. Conclusion: For all injected compounds, the relative microPET image intensity of the tumor matched the subsequently determined 86Y uptake. Coregistration with MR images confirmed the position of 86Y uptake relative to various organs. Radiolabeled trastuzumab mAb was shown to localize to sites of disease with minimal normal organ uptake. Dosimetry calculations showed a strong dependence on tumor size. These results demonstrate the usefulness of combined microPET and MRI for the evaluation of novel therapeutics.

Original languageEnglish (US)
Pages (from-to)1148-1155
Number of pages8
JournalJournal of Nuclear Medicine
Volume44
Issue number7
StatePublished - Jul 2003

Fingerprint

Pharmacokinetics
Carcinoma
Monoclonal Antibodies
Neoplasms
Radiopharmaceuticals
Trastuzumab
Spleen
Intraperitoneal Injections
Nude Mice
Calibration
Longitudinal Studies
Software
Kidney
Liver
Therapeutics

Keywords

  • MicroPET
  • Ovarian carcinoma
  • Pharmacokinetics
  • Trastuzumab; y

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model : Correlative MicroPET and MRI. / Palm, Stig; Enmon, Richard M.; Matei, Cornelia; Kolbert, Katherine S.; Xu, Su; Zanzonico, Pat B.; Finn, Ronald L.; Koutcher, Jason A.; Larson, Steven M.; Sgouros, George.

In: Journal of Nuclear Medicine, Vol. 44, No. 7, 07.2003, p. 1148-1155.

Research output: Contribution to journalArticle

Palm, S, Enmon, RM, Matei, C, Kolbert, KS, Xu, S, Zanzonico, PB, Finn, RL, Koutcher, JA, Larson, SM & Sgouros, G 2003, 'Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative MicroPET and MRI', Journal of Nuclear Medicine, vol. 44, no. 7, pp. 1148-1155.
Palm, Stig ; Enmon, Richard M. ; Matei, Cornelia ; Kolbert, Katherine S. ; Xu, Su ; Zanzonico, Pat B. ; Finn, Ronald L. ; Koutcher, Jason A. ; Larson, Steven M. ; Sgouros, George. / Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model : Correlative MicroPET and MRI. In: Journal of Nuclear Medicine. 2003 ; Vol. 44, No. 7. pp. 1148-1155.
@article{0bae09807767452d978576c8a37e4e56,
title = "Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: Correlative MicroPET and MRI",
abstract = "Preclinical biodistribution and pharmacokinetics of investigational radiopharmaceuticals are typically obtained by longitudinal animal studies. These have required the sacrifice of multiple animals at each time point. Advances in small-animal imaging have made it possible to evaluate the biodistribution of radiopharmaceuticals across time in individual animals, in vivo. MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of 90Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma. Methods: Female nude mice were inoculated intraperitoneally with 5.106 ovarian carcinoma cells (SKOV3). Fourteen days after inoculation, 12-18 MBq 86Y-labeled trastuzumab mAb was injected intraperitoneally. Tumor-free mice, injected with 86Y-trastuzumab, and tumor-bearing mice injected with labeled, irrelevant mAb or 86Y-trastuzumab + 100-fold excess unlabeled trastuzumab were used as controls. Eight microPET studies per animal were collected over 72 h. Standard and background images were collected for calibration. MicroPET images were registered with MR images acquired on a 1.5-T whole-body MR scanner. For selected time points, 4.7-T small-animal MR images were also obtained. Images were analyzed and registered using software developed in-house. At completion of imaging, suspected tumor lesions were dissected for histopathologic confirmation. Blood, excised normal organs, and tumor nodules were measured by γ-counting. Tissue uptake was expressed relative to the blood concentration (percentage of injected activity per gram of tissue [{\%}IA/g]/{\%}IA/g blood). 86Y-Trastuzumab pharmacokinetics were used to perform 90Y-trastuzumab dosimetry. Results: Intraperitoneal injection of mAb led to rapid blood-pool uptake (5-9 h) followed by tumor localization (26-32 h), as confirmed by registered MR images. Tumor uptake was greatest for 86Y-trastuzumab (7 ± 1); excess unlabeled trastuzumab yielded a 70{\%} reduction. Tumor uptake for the irrelevant mAb was 0.4 ± 0.1. The concentration in normal organs relative to blood ranged from 0 to 1.4 across all studies, with maximum uptake in spleen. The absorbed dose to the kidneys was 0.31 Gy/MBq 90Y-trastuzumab. The liver received 0.48 Gy/MBq, and the spleen received 0.56 Gy/MBq. Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm. Conclusion: For all injected compounds, the relative microPET image intensity of the tumor matched the subsequently determined 86Y uptake. Coregistration with MR images confirmed the position of 86Y uptake relative to various organs. Radiolabeled trastuzumab mAb was shown to localize to sites of disease with minimal normal organ uptake. Dosimetry calculations showed a strong dependence on tumor size. These results demonstrate the usefulness of combined microPET and MRI for the evaluation of novel therapeutics.",
keywords = "MicroPET, Ovarian carcinoma, Pharmacokinetics, Trastuzumab; y",
author = "Stig Palm and Enmon, {Richard M.} and Cornelia Matei and Kolbert, {Katherine S.} and Su Xu and Zanzonico, {Pat B.} and Finn, {Ronald L.} and Koutcher, {Jason A.} and Larson, {Steven M.} and George Sgouros",
year = "2003",
month = "7",
language = "English (US)",
volume = "44",
pages = "1148--1155",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "7",

}

TY - JOUR

T1 - Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model

T2 - Correlative MicroPET and MRI

AU - Palm, Stig

AU - Enmon, Richard M.

AU - Matei, Cornelia

AU - Kolbert, Katherine S.

AU - Xu, Su

AU - Zanzonico, Pat B.

AU - Finn, Ronald L.

AU - Koutcher, Jason A.

AU - Larson, Steven M.

AU - Sgouros, George

PY - 2003/7

Y1 - 2003/7

N2 - Preclinical biodistribution and pharmacokinetics of investigational radiopharmaceuticals are typically obtained by longitudinal animal studies. These have required the sacrifice of multiple animals at each time point. Advances in small-animal imaging have made it possible to evaluate the biodistribution of radiopharmaceuticals across time in individual animals, in vivo. MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of 90Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma. Methods: Female nude mice were inoculated intraperitoneally with 5.106 ovarian carcinoma cells (SKOV3). Fourteen days after inoculation, 12-18 MBq 86Y-labeled trastuzumab mAb was injected intraperitoneally. Tumor-free mice, injected with 86Y-trastuzumab, and tumor-bearing mice injected with labeled, irrelevant mAb or 86Y-trastuzumab + 100-fold excess unlabeled trastuzumab were used as controls. Eight microPET studies per animal were collected over 72 h. Standard and background images were collected for calibration. MicroPET images were registered with MR images acquired on a 1.5-T whole-body MR scanner. For selected time points, 4.7-T small-animal MR images were also obtained. Images were analyzed and registered using software developed in-house. At completion of imaging, suspected tumor lesions were dissected for histopathologic confirmation. Blood, excised normal organs, and tumor nodules were measured by γ-counting. Tissue uptake was expressed relative to the blood concentration (percentage of injected activity per gram of tissue [%IA/g]/%IA/g blood). 86Y-Trastuzumab pharmacokinetics were used to perform 90Y-trastuzumab dosimetry. Results: Intraperitoneal injection of mAb led to rapid blood-pool uptake (5-9 h) followed by tumor localization (26-32 h), as confirmed by registered MR images. Tumor uptake was greatest for 86Y-trastuzumab (7 ± 1); excess unlabeled trastuzumab yielded a 70% reduction. Tumor uptake for the irrelevant mAb was 0.4 ± 0.1. The concentration in normal organs relative to blood ranged from 0 to 1.4 across all studies, with maximum uptake in spleen. The absorbed dose to the kidneys was 0.31 Gy/MBq 90Y-trastuzumab. The liver received 0.48 Gy/MBq, and the spleen received 0.56 Gy/MBq. Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm. Conclusion: For all injected compounds, the relative microPET image intensity of the tumor matched the subsequently determined 86Y uptake. Coregistration with MR images confirmed the position of 86Y uptake relative to various organs. Radiolabeled trastuzumab mAb was shown to localize to sites of disease with minimal normal organ uptake. Dosimetry calculations showed a strong dependence on tumor size. These results demonstrate the usefulness of combined microPET and MRI for the evaluation of novel therapeutics.

AB - Preclinical biodistribution and pharmacokinetics of investigational radiopharmaceuticals are typically obtained by longitudinal animal studies. These have required the sacrifice of multiple animals at each time point. Advances in small-animal imaging have made it possible to evaluate the biodistribution of radiopharmaceuticals across time in individual animals, in vivo. MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of 90Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma. Methods: Female nude mice were inoculated intraperitoneally with 5.106 ovarian carcinoma cells (SKOV3). Fourteen days after inoculation, 12-18 MBq 86Y-labeled trastuzumab mAb was injected intraperitoneally. Tumor-free mice, injected with 86Y-trastuzumab, and tumor-bearing mice injected with labeled, irrelevant mAb or 86Y-trastuzumab + 100-fold excess unlabeled trastuzumab were used as controls. Eight microPET studies per animal were collected over 72 h. Standard and background images were collected for calibration. MicroPET images were registered with MR images acquired on a 1.5-T whole-body MR scanner. For selected time points, 4.7-T small-animal MR images were also obtained. Images were analyzed and registered using software developed in-house. At completion of imaging, suspected tumor lesions were dissected for histopathologic confirmation. Blood, excised normal organs, and tumor nodules were measured by γ-counting. Tissue uptake was expressed relative to the blood concentration (percentage of injected activity per gram of tissue [%IA/g]/%IA/g blood). 86Y-Trastuzumab pharmacokinetics were used to perform 90Y-trastuzumab dosimetry. Results: Intraperitoneal injection of mAb led to rapid blood-pool uptake (5-9 h) followed by tumor localization (26-32 h), as confirmed by registered MR images. Tumor uptake was greatest for 86Y-trastuzumab (7 ± 1); excess unlabeled trastuzumab yielded a 70% reduction. Tumor uptake for the irrelevant mAb was 0.4 ± 0.1. The concentration in normal organs relative to blood ranged from 0 to 1.4 across all studies, with maximum uptake in spleen. The absorbed dose to the kidneys was 0.31 Gy/MBq 90Y-trastuzumab. The liver received 0.48 Gy/MBq, and the spleen received 0.56 Gy/MBq. Absorbed dose to tumors varied from 0.10 Gy/MBq for radius = 0.1 mm to 3.7 Gy/MBq for radius = 5 mm. Conclusion: For all injected compounds, the relative microPET image intensity of the tumor matched the subsequently determined 86Y uptake. Coregistration with MR images confirmed the position of 86Y uptake relative to various organs. Radiolabeled trastuzumab mAb was shown to localize to sites of disease with minimal normal organ uptake. Dosimetry calculations showed a strong dependence on tumor size. These results demonstrate the usefulness of combined microPET and MRI for the evaluation of novel therapeutics.

KW - MicroPET

KW - Ovarian carcinoma

KW - Pharmacokinetics

KW - Trastuzumab; y

UR - http://www.scopus.com/inward/record.url?scp=0042889168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042889168&partnerID=8YFLogxK

M3 - Article

C2 - 12843231

AN - SCOPUS:0042889168

VL - 44

SP - 1148

EP - 1155

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 7

ER -